FR3068603B1 - Complement alimentaire pour proteger la fertilite feminine et masculine - Google Patents

Complement alimentaire pour proteger la fertilite feminine et masculine Download PDF

Info

Publication number
FR3068603B1
FR3068603B1 FR1756514A FR1756514A FR3068603B1 FR 3068603 B1 FR3068603 B1 FR 3068603B1 FR 1756514 A FR1756514 A FR 1756514A FR 1756514 A FR1756514 A FR 1756514A FR 3068603 B1 FR3068603 B1 FR 3068603B1
Authority
FR
France
Prior art keywords
family
vitamin
male fertility
food supplement
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1756514A
Other languages
English (en)
Other versions
FR3068603A1 (fr
Inventor
Marc Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuribiol
Original Assignee
Nuribiol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1756514A priority Critical patent/FR3068603B1/fr
Application filed by Nuribiol filed Critical Nuribiol
Priority to RU2019145156A priority patent/RU2019145156A/ru
Priority to MA48242A priority patent/MA48242A1/fr
Priority to CN201880046152.1A priority patent/CN111132679A/zh
Priority to CA3069353A priority patent/CA3069353A1/fr
Priority to US16/630,325 priority patent/US20200253260A1/en
Priority to EP18752543.1A priority patent/EP3651763A1/fr
Priority to PCT/FR2018/051623 priority patent/WO2019012199A1/fr
Publication of FR3068603A1 publication Critical patent/FR3068603A1/fr
Application granted granted Critical
Publication of FR3068603B1 publication Critical patent/FR3068603B1/fr
Priority to IL271900A priority patent/IL271900A/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

Le complément alimentaire suivant la présente invention pour protéger la fertilité féminine et masculine destiné à une administration par voie orale permettant de réduire d'une part les radicaux libres oxygénés provoquant des lésions de l'ADN et d'autre part Faction sur l'homocystéine dans son action délétère sur la méthylation, comprend en combinaison : • Un premier ingrédient constitué de bisglycinate de zinc ; • Un deuxième ingrédient formé à partir d'un acide aminé naturel de la famille des acides aminés N-acétyl-L cystéine ; • D'une première vitamine (B 12) appartenant à la famille des Cyanocobalamines sous une forme méthylée ; • D'une seconde vitamine (B2) issue de la famille des Riboflavine ; • D'une troisième vitamine (B6) provenant de la famille des chlorhydrates de pyridoxine ; • Et d'un troisième ingrédient formé à partir d'un acide lovémofolique et plus particulièrement à partir de l'acide 5–Méthyltétrahydrofolique
FR1756514A 2017-07-10 2017-07-10 Complement alimentaire pour proteger la fertilite feminine et masculine Active FR3068603B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR1756514A FR3068603B1 (fr) 2017-07-10 2017-07-10 Complement alimentaire pour proteger la fertilite feminine et masculine
MA48242A MA48242A1 (fr) 2017-07-10 2018-06-29 Complement alimentaire pour protéger la fertilité féminine et masculine
CN201880046152.1A CN111132679A (zh) 2017-07-10 2018-06-29 用于保护女性和男性生育力的食品补充剂
CA3069353A CA3069353A1 (fr) 2017-07-10 2018-06-29 Complement alimentaire pour proteger la fertilite feminine et masculine
RU2019145156A RU2019145156A (ru) 2017-07-10 2018-06-29 Пищевая добавка для защиты фертильности женщин и мужчин
US16/630,325 US20200253260A1 (en) 2017-07-10 2018-06-29 Food Supplement For Protecting Female and Male Fertility
EP18752543.1A EP3651763A1 (fr) 2017-07-10 2018-06-29 Complement alimentaire pour proteger la fertilite feminine et masculine
PCT/FR2018/051623 WO2019012199A1 (fr) 2017-07-10 2018-06-29 Complement alimentaire pour proteger la fertilite feminine et masculine
IL271900A IL271900A (en) 2017-07-10 2020-01-08 Food supplement for protecting female and male fertility

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1756514A FR3068603B1 (fr) 2017-07-10 2017-07-10 Complement alimentaire pour proteger la fertilite feminine et masculine
FR1756514 2017-07-10

Publications (2)

Publication Number Publication Date
FR3068603A1 FR3068603A1 (fr) 2019-01-11
FR3068603B1 true FR3068603B1 (fr) 2020-01-03

Family

ID=59859330

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1756514A Active FR3068603B1 (fr) 2017-07-10 2017-07-10 Complement alimentaire pour proteger la fertilite feminine et masculine

Country Status (9)

Country Link
US (1) US20200253260A1 (fr)
EP (1) EP3651763A1 (fr)
CN (1) CN111132679A (fr)
CA (1) CA3069353A1 (fr)
FR (1) FR3068603B1 (fr)
IL (1) IL271900A (fr)
MA (1) MA48242A1 (fr)
RU (1) RU2019145156A (fr)
WO (1) WO2019012199A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202017105380U1 (de) * 2017-09-06 2017-09-25 Aprofol Ag Folat-Zusammensetzungen
CN113069549B (zh) * 2021-04-22 2022-05-24 北京斯利安药业有限公司 一种用于改善精子质量的甲基供体组合物
CN113768913A (zh) * 2021-09-27 2021-12-10 南京百得生物科技有限公司 甜菜碱在制备改善卵巢功能的药物、食品、保健品的应用、药物、食品、保健品、动物模型

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733797B1 (en) * 2000-11-15 2004-05-11 William K. Summers Neuroceutical for improving memory and cognitive abilities
CA2445512C (fr) * 2001-04-25 2010-10-12 Cobalz Limited Methode de traitement ou de prevention d'une carence fonctionnelle en vitamine b12 chez un individu, et compositions medicales utilisees dans cette methode
CN103478718B (zh) * 2013-09-27 2015-10-28 美国东方生物技术（香港）有限公司 提高人体内谷胱甘肽浓度的功能食品及其制备方法
WO2017059895A1 (fr) * 2015-10-07 2017-04-13 Parthenogen Sagl Compléments alimentaires permettant de réaliser l'homéostasie oxy-rédox et la stabilité génomique

Also Published As

Publication number Publication date
FR3068603A1 (fr) 2019-01-11
EP3651763A1 (fr) 2020-05-20
RU2019145156A3 (fr) 2021-11-03
MA48242A1 (fr) 2021-06-30
IL271900A (en) 2020-02-27
US20200253260A1 (en) 2020-08-13
CA3069353A1 (fr) 2019-01-17
WO2019012199A1 (fr) 2019-01-17
CN111132679A (zh) 2020-05-08
RU2019145156A (ru) 2021-08-10

Similar Documents

Publication Publication Date Title
FR3068603B1 (fr) Complement alimentaire pour proteger la fertilite feminine et masculine
CY1124914T1 (el) Στερεες φαρμακευτικες συνθεσεις που περιεχουν αναστολεα ιντεγκρασης
PL378107A1 (pl) 1,2,4-triazyny hamujące HIV
GEP20125701B (en) Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile
MX2020005054A (es) Combinacion de dos agentes antivirales para el tratamiento de hepatitis c.
PH12013502277A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4 methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
CL2012002744A1 (es) Compuesto inhibidor no nucleosídico de la transcriptasa inversa derivado de 3-(hidrocarbiloxi aromático y alifático opcionalmente sustituido)-1-[(5-oxo-4,5-dihidro-1h-1,2,4-triazol-3-il)metil])-piridin-2(ih)-ona; composición farmacéutica que lo comprende útil en la profilaxis y tratamiento de la infección por vih y sida.
CO7051027A2 (es) Agentes antivirales contra la hepatitis b
MX2021001905A (es) Preparacion farmaceutica que tiene excelentes propiedades de disolucion, que contiene esomeprazol y bicarbonato de sodio.
ATE482953T1 (de) Hiv-inhibierende 5-(hydroxymethylen- und aminomethylen) substituierte pyrimidine
ECSP066826A (es) Inhibidores de integrasa de vih
PH12017500724B1 (en) Carbazole derivatives
EA201890507A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
AR054525A1 (es) Composiciones y metodos para eltratamiento de sintomas relacionados con el ciclo
MX2016014771A (es) Forma de dosificacion oralmente desintegrante para administracion de avanafil, y metodos de fabricacion y uso asociados.
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
ZA202301198B (en) Method of treating diseases
DE60324014D1 (de) Heterocyclische verbindungen alsccr5-antagonisten
MA32275B1 (fr) Preparations orales et injectables de composes de tetracycline
GT200300227A (es) Formulaciones de liberacion prolongada en forma de suspension
DK1638582T3 (da) Anvendelse af hyaluronsyre til fremstilling af kompositioner til behandling af tilbagevendende after
WO2008050133A3 (fr) Inhibition d'une agrégation de beta-amyloïde
GEAP202115242A (en) Combination of mcl-1 inhibitor and standard of care treatment for hematologic cancers, uses and associated pharmaceutical compositions
MXPA04006120A (es) Piperidin-2,6-dionas sustitudas heterociclicamente en posicion 3.
Gonella Fluorouracil/folinic acid/oxaliplatin

Legal Events

Date Code Title Description
PLSC Publication of the preliminary search report

Effective date: 20190111

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9